You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

November 5, 2018

Myanmar-Language Labeling Required on Wide Range of Products

Myanmar’s Central Committee for Consumer Protection issued Notification 1/2018 on October 26, 2018, which requires labels containing certain information in Myanmar language, jointly or combined with another language, to be affixed to certain products sold in the country. The notification is intended to ensure the safety of consumers.

The notification states that Myanmar-language labels must contain the following information:

  • Directions for use;
  • Storage instructions;
  • Allergy alerts and/or warnings; and
  • Side effects (if any).

The Myanmar-language label must be affixed to consumer units, jointly or combined with labelling in another language, but the legislation does not cover other packaging, such as display boxes.

The list of priority products that require Myanmar-language labelling, jointly or combined with labelling in another language, is as follows: 

The committee may announce other products to be included in the list in the future.

Companies will have a six-month grace period from the notification date (October 26, 2018) to comply with the new regulation. Any violations after the grace period will leave companies vulnerable to the following sanctions under Section 19 of the Myanmar Consumer Protection Law 2014:

  • warning;
  • severe warning;
  • order to remedy the violation or compensate;
  • temporary prohibition of the sale and distribution of goods in violation;
  • product recall;
  • destruction of goods; and/or,
  • temporary or permanent revocation of business licenses or permits.

RELATED INSIGHTS​ 

May 3, 2011
The variety and ever-changing nature of regulations governing patent and drug approvals across the Asian region, along with policies which often favor local generics, can pose a daunting challenge for multinational research-based pharmaceutical companies. This article takes a look at some of the major issues and how they can be addressed.
May 3, 2011
In the last decade, Thailand has established the objective of becoming a regional player in the pharmaceutical industry. In 2004, the Thai government adopted a five-year plan to develop the capacity of the country to become a Center of Excellence in the region. The government has only partially achieved this objective. Thailand continues to lag behind its competitors in certain areas, notably with regard to the implementation of policies relating to pharmaceutical products.
May 3, 2011
Thailand’s attempt to become a regional medical hub is being held back by pro-generic policies and burdensome regulatory approval processes. This article examines three obstacles to Thailand’s aim.